Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 9, 2013, Pages 782-791

  Liu, Jianwei ^a   Wang, Zhu ^a   He, Jintian ^a   Wang, Gaizhen ^b   Zhang, Rongbo ^a   Zhao, Baohua ^a  

^a HEBEI NORMAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fibrinolytic activity; Immunogenicity; Pharmacokinetic; Site specific pEGylation; Staphylokinase

Indexed keywords

AUR PROTEIN, STAPHYLOCOCCUS AUREUS; MACROGOL DERIVATIVE; METALLOPROTEINASE; PLASMINOGEN; PRIMER DNA;

ANIMAL; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STABILITY; FIBRINOLYSIS; IMMUNOLOGY; KINETICS; METABOLISM; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; KINETICS; METALLOENDOPEPTIDASES; PLASMINOGEN; POLYETHYLENE GLYCOLS; RABBITS;

EID: 84911430133     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu068     Document Type: Article

References (29)

1. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 1998, 4: 279-284.
2. Collen D, Moreau H, Stockx L and Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation 1996, 94: 207-216.
3. Kang JS, Deluca PP and Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009, 14: 363-380
4. Pasut G and Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012, 161: 461-472.
5. Vanwetswinkel S, Plaisance S, Zhang ZY, Vanlinthout I, Brepoels K, Lasters I and Collen D, et al. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood 2000, 95: 936-942.
6. Collen D, Sinnaeve P, Demarsin E, Moreau H, De Maeyer M, Jespers L and Laroche Y, et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation 2000, 102: 1766-1772.
7. Moreadith RW and Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003, 55: 1337-1345.
8. Laroche Y, Heymans S, Capaert S, De Cock F, Demarsin E and Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000, 96: 1425-1432.
9. Xue X, Li D, Yu J, Ma G, Su Z and Hu T. Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase. Biomacromolecules 2013, 14: 331-341.
10. Wang J, Hu T, Liu Y, Zhang G, Ma G and Su Z. Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase. Anal Biochem 2011, 412: 114-116.
11. Mu Q, Hu T and Yu J. Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation. PLoS ONE, 2013, 8: e68559.
12. Warmerdam PA, Vanderlick K, Vandervoort P, De Smedt H, Plaisance S, De Maeyer M and Collen D. Staphylokinase-specific cell-mediated immunity in humans. J Immunol 2002, 168: 155-161.
13. Collen D, Bernaerts R, Declerck P, De Cock F, Demarsin E, Jenne S and Laroche Y, et al. Recombinant staphylokinase variants with altered immunoreactivity. I: construction and characterization. Circulation 1996, 94: 197-206.
14. He J, Xu R, Chen X, Jia K, Zhou X and Zhu K. Simultaneous elimination of T- and B-cell epitope by structure-based mutagenesis of single Glu80 residue within recombinant staphylokinase. Acta Biochim Biophys Sin (Shanghai) 2010, 42: 209-215.
15. Cavallo L, Kleinjung J and Fraternali F. POPS: a fast algorithm for solvent accessible surface areas at atomic and residue level. Nucleic Acids Res 2003, 31: 3364-3366.
16. Ohlenschlager O, Ramachandran R, Guhrs KH, Schlott B and Brown LR. Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase. Biochemistry 1998, 37: 10635-10642.
17. Schwede T, Kopp J, Guex N and Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31: 3381-3385.
18. Su HB, Zhang YG, He JT, Mo W, Zhang YL, Tao XM and Song HY. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity. Acta Biochim Biophys Sin (Shanghai) 2004, 36: 336-342.
19. Nakane PK and Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem 1974, 22: 1084-1091.
20. Veronese FM and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10: 1451-1458.
21. Cohan RA, Madadkar-Sobhani A, Khanahmad H, Roohvand F, Aghasadeghi MR, Hedayati MH and Barghi Z, et al. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int J Nanomedicine 2011, 6: 1217-1227.
22. Gaberc-Porekarm V, Zore I, Podobnik B and Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 2008, 11: 242-250.
23. Harris JM and Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2: 214-221.
24. Rodriuez-Martinez JA, Sola RJ, Castillo B, Cintron-Colon HR, Rivera-Rivera I, Barletta G and Griebenow K. Stabilization of alphachymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol Bioeng 2008, 101: 1142-1149.
25. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008, 97: 4167-4183.
26. Kumar S, Singh SK, Wang X, Rup B and Gill D. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 2011, 28: 949-961.
27. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ and Saifer MG. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem 2012, 23: 485-499.
28. Garay RP, El-Gewely R, Armstrong JK, Garratty G and Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012, 9: 1319-1323.
29. Ueshima S and Matsuo O. Development of new fibrinolytic agents. Curr Pharm Des 2006, 12: 849-857.